A quantitative PET imaging method was used to assess the in vivo kinetics of hepatobiliary and renal excretion of the breast cancer resistance protein (Bcrp) substrate 11 C-SC-62807 in mice. Methods: Serial abdominal PET scans were collected in wild-type and Bcrp knockout (Bcrp -/-) mice after intravenous injection of 11 C-SC-62807. Venous blood samples and PET images were obtained at frequent intervals up to 30 min after radiotracer administration. Dynamic PET data were analyzed to determine the canalicular and brush-border efflux clearances in the liver and kidney (CL int,bile,liver and CL int,urine,kidney , respectively). Results: SC-62807 is an in vitro substrate of mouse Bcrp and human BCRP. Radioactivity associated with 11 C-SC-62807 was predominantly found in the blood, liver, bile, and urine 30 min after administration. Both biliary and urinary excretion of radioactivity was markedly lower in Bcrp -/-mice than in wild-type mice, suggesting greater systemic exposure in Bcrp -/-mice. Both the CL int,bile,liver and the CL int,urine,kidney were significantly lower in Bcrp -/-mice (74% 6 10% and 99% 6 1% lower than controls, respectively). We also found that 11 C-SC-62807 is a substrate of the organic anion-transporting polypeptides OATP1B1 and OATP1B3 in vitro. Conclusion: The present study demonstrated that Bcrp plays a significant role in the efflux of 11 C-SC-62807 in mouse liver and kidney. We also demonstrated the feasibility of PET using 11 C-SC-62807 to study the activity of BCRP in humans.
Drug transporters play an important role in drug disposition and may influence therapeutic efficacy or development of adverse drug reactions (1) (2) (3) . The breast cancer resistance protein (Bcrp, rodents; BCRP/ABCG2, humans) is a member of the adenosine triphosphate (ATP)-binding cassette transporter G family and mediates the efflux transport of endobiotics and xenobiotics coupled with ATP hydrolysis (4) (5) (6) . BCRP is expressed in various normal tissues, including liver, kidney, brain, placenta, and intestine, where it is expressed on the brush-border membranes of epithelial cells (7) . Cumulative in vivo studies, particularly involving Bcrp knockout (Bcrp -/-) mice, have demonstrated the important role BCRP plays in drug disposition, limiting oral absorption and penetration into the brain and testis (8) , and mediating biliary and urinary excretion of xenobiotics such as pitavastatin and methotrexate (1, (9) (10) (11) . Pharmacogenomic studies focusing on a single nucleotide polymorphism frequently observed in Asians (421C.A) elucidated the importance of BCRP in systemic exposure to orally administered sulfasalazine and rosuvastatin (12, 13) . Because of the lack of a suitable probe, the role of BCRP in the elimination of BCRP substrates from the systemic circulation and their distribution in the brain has not been investigated. Furthermore, because BCRP eliminates uric acid, mutations and single nucleotide polymorphisms in this protein make it a risk factor for gout and are thus drawing increasing research interest (14) . The many important roles played by BCRP make it a subject of major clinical interest.
PET is a powerful noninvasive molecular imaging technique that provides high sensitivity and good spatiotemporal resolution, enabling determination of the tissue concentration of drugs labeled with a positron-emitting radionuclide (15) (16) (17) . The usefulness of transporter probes for molecular imaging has been demonstrated through in vivo phenotypic measurements of altered hepatobiliary transport of organic anion-transporting polypeptide (Oatp, rodents; OATP, humans) and multidrug resistance-associated protein 2 (Mrp2, rodents; MRP2, humans) in preclinical and clinical tests using 99m Tc-mebrofenin (18) and 15R-11 C-TIC-Me (19, 20) . Recently, functional PET probes for Bcrp and P-glycoprotein, such as 11 C-elacridar and 11 C-gefitinib, have been described for use in the noninvasive in vivo evaluation of these proteins at the blood-brain barrier (BBB) (21, 22) . However, because the major elimination pathway of these probes is metabolism, they cannot be used to evaluate efflux activity in the liver and kidney.
SC-62807 is the major metabolite of celecoxib (a selective cyclooxygenase-2 inhibitor) and is produced by CYP2C9 (23) . Because SC-62807 contains a carboxylate group and does not undergo further metabolism, we hypothesized that SC-62807 would be a good probe for certain efflux transporters in the liver, and we synthesized 11 C-SC-62807 for this purpose ( ½Fig: 1 Fig. 1 ). We previously demonstrated that in rats 11 C-SC-62807 is rapidly excreted into the bile without further metabolism (24) . In this study, we elucidated the predominant role of Bcrp in the efflux of SC-62807 into the bile and urine in mice and demonstrate the feasibility of using PET to evaluate BCRP activity in humans.
MATERIALS AND METHODS
Celecoxib carboxylic acid (SC-62807) was purchased from Toronto Research Chemicals Inc. 11 C-SC-62807 was synthesized according to previously reported procedures (24) . The chemical purity of 11 C-SC-62807 was determined by measuring the ultraviolet absorbance at 254 nm. The radiochemical purity was greater than 98%, and the specific radioactivity was 14 6 10 GBq/mmol at the time of injection. All chemicals and solvents used for labeling synthesis were analytic grade.
Animals
Male wild-type FVB and Bcrp -/-mice were purchased from Taconic Inc. (age, 6-12 wk, weight, 22-30 g). Mice were maintained in a temperature-and light-controlled environment with ad libitum access to standard food and tap water. All experimental protocols were approved by the Ethics Committee on Animal Care and Use of the Center for Molecular Imaging Science at RIKEN and were performed in accordance with the Guide for the Care and Use of Laboratory Animals (25) .
Determination of ATP-Dependent Uptake of SC-62807 by Transporter-Expressing Membrane Vesicles
Membrane vesicles were prepared as described previously from HEK293 cells infected with adenoviruses expressing mouse Bcrp (mBcrp), human BCRP (hBCRP), and green fluorescent protein (GFP) (control) (26) and with recombinant adenoviruses containing human MRP2 and tetracycline-responsive transcriptional activator (27) . A rapid filtration technique was used to assess ATP-dependent uptake (26) . Samples were quantified using liquid chromatographytandem mass spectrometry. The level of ATP-dependent uptake was calculated by subtracting the uptake into vesicles in the presence of adenosine monophosphate (AMP) from that in the presence of ATP. Kinetic parameters were calculated using the Michaelis-Menten equation:
where v represents the uptake velocity of the substrate, S represents the substrate concentration in the medium, K m represents the Michaelis constant, and V max represents the maximum uptake velocity. The nonlinear least-squares method was used for fitting (Damping Gauss-Newton method algorithm) with the MULTI program (28) .
PET Studies
All PET scans were obtained using a microPET Focus220 scanner (Siemens) designed for laboratory animals. Mice were anesthetized and maintained with a mixture of 1.5% isoflurane and oxygen and then placed on the PET scanner gantry. An emission scan was performed after intravenous bolus injection of 11 C-SC-62807 (158 6 32 MBq/kg) via a catheter inserted into the tail. The bolus injections contained 0.23 6 0.19 mg of SC-62807 per animal. An emission scan was obtained in 3-dimensional list mode for 30 min and sorted into 26 dynamic sinograms according to the following sequence: 12 · 5, 3 · 20, 3 · 60, 5 · 120, and 3 · 300 s. Blood was sampled via the tail vein at the following time points: 2, 5, 15, 30, and 60 min after radiotracer administration. In addition, the biodistribution in a separate group of mice was also determined. After blood and urine sampling, blood flow was terminated by exsanguination via aortic puncture, and the liver and kidneys were quickly removed, weighed, and assayed for regional radioactivity using a 1470 Wizard automatic g-counter (PerkinElmer). The radioactivity measured in each sample was decay-corrected to the injection time and expressed as percentage dose per tissue or percentage dose per milliliter of blood, normalized to the injected radioactivity.
Radiometabolite Analysis
Radiometabolites in the blood, urine, liver, and bile of a separate group of mice (n 5 2) were analyzed using radiometric high-performance liquid chromatography. Blood and urine were collected 15 min after the mice received an intravenous injection of 11 C-SC-62807 (;211 6 21 MBq/kg), and bile was sampled from the gallbladder 30 min after injection. To sample liver tissue, blood flow was terminated 15 min after administration, and the liver was quickly removed and homogenized. Sample preparation and chromatographic separation were performed as described previously (24) .
Analysis of PET Data
PET images were reconstructed using microPET Manager 2.4.1.1 (Siemens) by standard 2-dimensional filtered backprojection using a ramp filter with a cutoff at the Nyquist frequency. Regions of interest representing the liver and the intestines were delineated using PMOD software (version 3.0; PMOD Technologies Ltd.), as described previously (19) . In this PET analysis, the sum of the radioactivity in the gallbladder and intestine corresponds to the radioactivity in the bile secreted to these tissues because a conventional biodistribution study revealed that the bile radioactivity sampled from rats with bile duct cannulas is comparable to that in the intestine as determined by PET image analysis (24) . A time profile of the radioactivity in each tissue was constructed by normalizing decay-corrected time-radioactivity measurements to the injected dose (percentage dose) of 11 C-SC-62807.
The biliary secretion clearance (CL bile,blood,0-30 min ) and renal clearance (CL renal,blood,0-30 min ) with respect to the blood radioactivity concentration were calculated using the following equations: CL bile;blood;0230min 5 X bile;0230min =AUC blood;0230min
Eq. 2 and CL urine;blood;0230min 5 X urine;0230min =AUC blood;0230min ; Eq. 3
where X represents the amount of radioactivity secreted into the bile or urine between 0 and 30 min, and AUC blood,0-30 min represents the area under the blood radioactivity concentration-time curve for the time period 0-30 min.
The apparent tissue-to-blood area under the curve (AUC) ratio (K p,liver,AUC or K p,kidney,AUC ) was calculated using the following equation:
Eq. 4
where AUC tissue,0-30 min represents the area under the tissue radioactivity concentration-time curve for the time period 0-30 min. Canalicular efflux clearance (CL int,bile,liver ) was estimated by integration plot analysis using noninvasive measurements of radioactivity in the liver and bile encompassing about the first 27.5 min after 11 C-SC-62807 administration, during which the plot shows linear regression. Kidney brush-border efflux clearance with respect to the kidney concentration (CL int,urine,kidney ) was estimated by integration plot analysis using the radioactivity in the kidney and urine encompassing about the first 6 min after 11 C-SC-62807 administration for wild-type mice and the first 27.5 min after administration for Bcrp -/-mice. Biliary efflux and kidney brush-border efflux clearances were calculated using the following equations: X t;bile 5 CL int;bile;liver · AUC 02t;liver 1 X E;bile Eq. 5 and X t;urine 5 CL int;urine;kidney · AUC 02t;kidney 1 X E;urine ; Eq. 6 where X t,bile and X t,urine represent the amount of radioactivity excreted into the bile and urine, respectively, at time t as determined by PET image analysis. The areas under the hepatic and renal concentration-time curves from time 0 to time t are represented by AUC 0-t,liver and AUC 0-t,kidney , respectively. The CL int,bile,liver and CL int,urine,kidney can be obtained from the slopes of plots of X t,bile versus AUC 0-t,liver and X t,urine versus AUC 0-t,kidney , respectively. Values for X E,urine and X E,bile were determined from the y-intercept of the respective integration plots, representing the initial distribution in these regions of interest (tissues) at time 0.
Uptake by Transporter-Expressing HEK293 Cells OATP1B1-and OATP1B3-expressing HEK293 cells were established previously (29) . The transport study was performed as described previously (29) . Briefly, cells were seeded onto 12-well plates coated with poly-L-lysine and poly-L-ornithine. After 2 d, the culture medium was replaced with medium supplemented with 5 mM sodium butyrate, and cells were incubated for 24 h before the transport study to induce transporter expression. Cells were then washed and preincubated with Krebs-Henseleit buffer. Uptake was initiated by adding buffer containing radiolabeled compounds or unlabeled SC-62807 and terminated at the designated time by adding ice-cold buffer after removal of the incubation buffer. To assess uptake of radiolabeled compounds, cells were solubilized with 0.2N NaOH and kept overnight at 4°C. After neutralization with HCl, aliquots were transferred to scintillation vials and radioactivity associated with the cells and incubation buffer was measured using a liquid scintillation counter (LS6000SE; Beckman Coulter) after the addition of scintillation cocktail (Clear-sol I; Nacalai Tesque). To assess uptake of SC-62807, cells were solubilized in H 2 O by sonication on ice. Aliquots of the cell lysate were extracted with ethyl acetate, and sulfasalazine was used as the internal standard. After centrifugation, the supernatants were evaporated, reconstituted with 10 mM ammonium acetate/methanol (40:60, v/v), and quantitatively analyzed using liquid chromatography-tandem mass spectrometry. The remaining cell lysate was used to determine the protein concentration using the Lowry method with bovine serum albumin as a standard.
Estimating Contribution of OATP1B1 and OATP1B3 to SC-62807 Uptake by Human Hepatocytes
The contribution of OATP1B1 and OATP1B3 to SC-62807 uptake by human hepatocytes was estimated using relative activity factor analysis, as described in detail elsewhere (28, 29 The uptake clearance of SC-62087 in hepatocytes (CL hepatocytes,SC ) was estimated as the product of the R values (R 1B1 and R 1B3 ) and uptake clearance of SC-62087 in OATP1B1-and OATP1B3-expressing HEK293 cells (CL OATP1B1,SC and CL OATP1B3,SC ) using the following equation:
Eq. 9
The contributions of OATP1B1 and OATP1B3 are defined as the product of R 1B1 and CL 1B1,SC divided by CL hepatocyte,SC and the product of R 1B3 and CL 1B3,SC divided by CL hepatocyte,SC , respectively.
Statistical Analysis
Data are presented as the mean 6 SD for 3-4 determinations. The statistical significance of differences between groups was de-
RESULTS

ATP-Dependent Uptake of SC-62807 into mBcrp-or hBCRP-Expressing Membrane Vesicles
Uptake of SC-62807 by membrane vesicles expressing mBcrp or hBCRP was markedly stimulated in the presence of ATP but not in the presence of AMP or in vesicles prepared from control cells ( ½Fig: 2 Fig. 2A) . Uptake of SC-62807 was saturable and followed Michaelis-Menten kinetics, with K m and V max values of 19.9 6 3.9 mM and 435 6 50 pmol/min/mg of protein, respectively, for mBcrp and 10.4 6 1.73 mM and 2,263 6 204 pmol/min/mg of protein, respectively, for hBCRP (Fig. 2B) . Radioactivity localized primarily in the liver and kidneys within 2 min of 11 C-SC-62807 administration in both wildtype and Bcrp -/-mice and subsequently moved to the intestine (derived from bile) or the urinary bladder (derived from urine) in wild-type mice by 30 min after administration ( ½Fig: 3 Fig. 3A ). In contrast, translocation of radioactivity to the intestine and urinary bladder was markedly delayed in Bcrp -/-mice (Fig. 3B) .
Mouse abdominal region tissue and blood radioactivity time profiles are shown in ½Fig: 4 Figure 4 . A maximum of 35% 6 8% and 14% 6 3% of the dose was distributed in the liver and kidney, respectively, of wild-type mice by 2 min after administration, after which the amount of radioactivity declined rapidly. In contrast, radioactivity in the liver and kidney of Bcrp -/-mice reached a maximum at 4 and 18 min, respectively, and then decreased gradually. Radioactivity in the bile (sum of gallbladder and intestine) and urine of wild-type mice increased until 30 min, reaching 48% 6 3% and 26% 6 5% of the dose, respectively, whereas the level of radioactivity in the bile and the urine was much lower. A separate conventional biodistribution study revealed that in wild-type and Bcrp 2/2 mice, the radiotracer is distributed primarily in the liver (34% and 44% of dose, respectively) and to a lesser degree in the kidneys (3% and 16% of dose) and urine (7% and 0.02% of dose) at 5 min after administration. At 30 min, radioactivity in the liver, kidney, and urine of wild-type and Bcrp 2/ 2 mice was 10% and 25%, 0.4% and 14%, and 5% and 9% of the dose, respectively. These data were comparable to the PET data. Radioactivity in the blood decreased rapidly in wild-type mice but decreased only slightly and then remained constant in Bcrp -/-mice. The AUC blood,0-30 min for Bcrp -/-mice (93% 6 19% of the dose · min/mL) was 2.2-fold higher than that for wild-type mice (42% 6 18% of the dose · min/mL) ( ½Table 1 Table 1 ). The liver-to-blood AUC ratio (K p,liver,AUC ) was lower in Bcrp -/-mice than in wild-type mice; however, the difference was not statistically significant. The kidney-to-blood AUC ratio (K p,kidney,AUC ) was significantly higher in Bcrp -/-mice than in wild-type mice (P , 0.01) ( Fig. 4 ; Table 1 ). High-performance liquid chromatography analysis revealed that almost 100% of the radioactivity in the blood, liver, bile, and urine represented unchanged 11 C-SC-62807 ( ½Fig: 5 Fig. 5 ), indicating that in mice 11 C-SC-62807 is rapidly eliminated without further metabolism via hepatobiliary and renal excretion.
Canalicular Efflux and Kidney Brush-Border Efflux Clearance of 11 C-SC262807 in Mice
Clearance of radioactivity via canalicular and kidney brush-border efflux (CL int,bile,liver and CL int,urine,kidney , jnm110254-pm n 1/3/13 Unpaired t test, P , 0.001. Each value represents mean 6 SD (n 5 3-4). Statistically significant difference was observed for several pharmacokinetic parameters in Bcrp -/-mice, compared with wild-type.
and OATP1B3 was similar in human hepatocytes as determined by R values (Table 2) .
DISCUSSION
BCRP is an ATP-binding cassette transporter involved in biliary and renal excretion. The purpose of this study was to clarify the utility of 11 C-SC-62807 as a PET probe for analyzing the function of Bcrp in biliary and renal excretion in experimental animals and to demonstrate the feasibility of using 11 C-SC-62807 to assess BCRP function in humans. PET studies with 11 C-SC-62807 were designed to examine the kinetics of hepatobiliary transport and renal excretion in mice.
In vitro transport studies using mBcrp-and hBCRPexpressing membrane vesicles showed that SC-62807 is a substrate for BCRP in both mice and humans. This finding prompted us to investigate the tissue distribution and significance of Bcrp in the elimination of SC-62807 from the systemic circulation because Bcrp is normally expressed in the canalicular membrane of hepatocytes and the brushborder membrane on the proximal tubules in rodents (1) as well as in the BBB and blood-placenta barrier.
PET revealed that 11 C-SC-62807 is excreted into the bile and urine. Because radiometabolite analyses indicated that radioactivity associated with 11 C-SC-62807 metabolites is negligible in the blood, liver, bile, and urine of mice, the total radioactivity represents the unchanged form. After intravenous bolus injection, 11 C-SC-62807 is predominantly excreted into the bile and, to a slightly lesser extent, into the urine. About 74% of the radioactivity was recovered in the bile and urine of wild-type mice within 30 min of administration. The 11 C-SC-62807 CL renal,blood,0-30 min was greater than the reported creatinine clearance value (8.7 6 2.0 mL/min/kg) (30) , indicating that tubular secretion contributes significantly to renal excretion.
Because BCRP is expressed in the apical membrane, its transport activity is tightly associated with the intrinsic efflux activity across the canalicular and brush-border membranes (CL int,bile,liver and CL int,urine,kidney ). An advantage of PET is that it enables noninvasive monitoring of the tissue concentration to determine these parameters. Our PET analysis demonstrated that both biliary and renal excretion of 11 C-SC-62807 is significantly reduced in Bcrp -/-mice, leading to prolonged systemic exposure to 11 C-SC-62807. The marked decrease in both CL int,bile,liver and CL int,urine,kidney in Bcrp -/-mice clearly indicates that the predominant contribution of Bcrp to efflux of 11 C-SC-62807 into the bile and urine. The transporter Mrp2 is indispensable to the efflux of most anionic drugs into the bile. SC-62807 was also shown to be an in vitro substrate for Mrp2 using an uptake study involving MRP2-expressing membrane vesicles. However, the V max /K m (5.6 6 1.5 mL/min/mg of protein) was much lower than that for BCRP-expressing vesicles (218 6 41 mL/min/mg of protein). There was only a slight decrease in the radioactivity excreted into the bile in Mrp2-deficient rats, compared with normal rats (data not shown). These results confirmed the specificity of SC-62807 for Bcrp in canalicular efflux. Consistent with the marked reduction in efflux into the urine, the 11 C-SC-62807 K p,kidney was significantly higher in Bcrp -/-mice than in wild-type mice. Despite the marked reduction in CL int,bile,liver , however, the K p,liver,AUC was lower in Bcrp -/-mice, possibly due either to a low contribution of canalicular efflux to the net efflux from hepatocytes or to adaptive regulation caused by a Bcrp defect. The transporter Mrp3 is expressed on the sinusoidal membrane of hepatocytes, where it mediates the sinusoidal efflux of anionic drugs and glucuronide conjugates into the blood. Sinusoidal efflux mediated by Mrp3 may contribute significantly to net hepatocytic efflux, thereby attenuating the impact of Bcrp defects on the liver-to-plasma ratio. A reduction in influx mediated by an unknown mechanism or elevation in sinusoidal efflux may also explain the discrepancy, although there are no reports concerning adaptive regulation in the expression of drug transporters in the liver of Bcrp -/-mice. We found that SC-62807 is a good in vitro substrate of OATP1B1 and OATP1B3 (Table 2) . It is quite possible that rodent isoforms can mediate hepatic uptake of SC-62807. Further investigation is necessary to elucidate the mechanism underlying the discrepancy.
We also conducted 11 C-SC-62807 PET of mouse brain regions to demonstrate the utility of the technique for examining Bcrp function at the BBB. Brain penetration of 11 C-SC-62807 was low in both wild-type and Bcrp -/-mice, with the apparent tissue-to-blood concentration ratio (K p ) values around 0.03 (Supplemental Fig. 1 ; supplemental materials are available online only at http://jnm.snmjournals.org). Generally, anionic drugs have low distribution volumes in the brain, presumably because of high protein binding in the plasma and low membrane permeability of the BBB. Thus, we concluded that the use of this probe for examining Bcrp function at the BBB may be impractical because of the likelihood of poor transport across the BBB.
PET enables the direct noninvasive measurement of intrinsic efflux across the canalicular and brush-border membranes. Using PET, we detected a marked reduction in canalicular and brush-border efflux of the radioactivity associated with 11 C-SC-62807 in Bcrp 2/2 mice, demonstrating the feasibility of clinical investigations of BCRP variation using 11 C-SC-62807 as a radiotracer. It was reported that SC-62807, which is produced by oxidation of the antiinflammatory drug celecoxib, is found predominantly in the feces and urine after oral celecoxib administration in humans and that the amount of the glucuronide conjugate metabolite is low in both feces and urine (31) , suggesting that 11 C-SC-62807 should be minimally metabolized in humans when administered as an intravenous injection. The fact that SC-62807 is a good substrate of OATP1B1 and OATP1B3 in vitro suggests that SC-62807 is efficiently taken up by the liver from the blood circulation. In humans, SC-62807 is most likely excreted into the bile by transporters. These characteristics fulfill the conditions required for in vivo PET. Clinical studies with 11 C-SC-62807 could elucidate the importance of BCRP in the disposition of drugs in humans and help resolve questions over interindividual differences in BCRP activity in the liver caused by genetic polymorphisms and sex differences.
CONCLUSION
We demonstrated the utility of noninvasive PET using 11 C-SC-62807 as a radiotracer for the functional characterization of Bcrp, a protein responsible for biliary and renal excretion. We also showed the feasibility of using this technique to assess BCRP-associated membrane transport in hepatobiliary and renal excretion in humans.
DISCLOSURE
The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734. This work was supported by a Grant-in-Aid for Young Scientists (B) (KAKENHI 21790171) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japanese government. This work was also supported by a Grant-in-Aid for Scientific Research on Innovative Areas HD-Physiology (23136101) from the Ministry of Education, Science, and Culture of Japan. No potential conflict of interest relevant to this article was reported.
